Skip to main content
Fig. 5 | Alzheimer's Research & Therapy

Fig. 5

From: Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound

Fig. 5

Prevention of dendritic and synaptic deficits by P021 in 3 × Tg-AD mice at 15 months posttreatment. After 15 months, P021- (Tg-AD-P021) and vehicle-treated (Tg-AD vh) animals were euthanized, and expressions of MAP2, synapsin 1, GluR1, synaptophysin, and NR1 were studied immunohistochemically. a Immunohistochemical staining of MAP2 in CA1 (stratum radiatum and stratum pyramidae), CA3 (stratum oriens, stratum radiatum, and stratum pyramidae), dentate gyrus (DG; entire area), and parietal cortex (all six layers); b synapsin 1 in CA1, CA3, and parietal cortex; c GluR1 in CA1; d synaptophysin in CA1 and parietal cortex; e NR1 in DG and parietal cortex. f Quantification of immunohistochemical staining. The 3 × Tg-AD-vh mice show a deficit in the expression of MAP2 and GluR1, and P021 was able to rescue this deficit. *p < 0.05, **p < 0.01, by one-way ANOVA post-hoc test. Scale bar = 100 μm. Wild-type (WT), n = 5; 3 × Tg-AD-vh, n = 4; 3 × Tg-AD-P021, n = 5. Each maximum projection picture to be analyzed was converted to greyscale and each area to be analyzed was selected, the threshold was adjusted, and the mean pixel intensity of the region of interest was quantified. Quantification is shown as mean ± SD

Back to article page